Value-based pricing: incentive for innovation or zero net benefit?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.International journal of environmental research and public health · 2020
   Pooled it
2. Application of four pricing models for orphan medicines: a case study for lumasiran.Orphanet journal of rare diseases · 2024
   Article
3. Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia.JAMA pediatrics · 2022
   Article
4. Stakeholder opinions on value in healthcare.European journal of hospital pharmacy : science and practice · 2019
   Article
5. New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes.PharmacoEconomics · 2018
   Article
6. The Value of Medicines: A Crucial but Vague Concept.PharmacoEconomics · 2016
   Review
7. The Irish Cost-Effectiveness Threshold: Does it Support Rational Rationing or Might it Lead to Unintended Harm to Ireland's Health System?PharmacoEconomics · 2016
   Article
8. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales.British journal of cancer · 2014
   Article
9. Market access of cancer drugs in European countries: improving resource allocation.Targeted oncology · 2014
   Review
10. A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.Cost effectiveness and resource allocation : C/E · 2014
    Article
11. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.PharmacoEconomics · 2013
    Article
12. Operationalizing value-based pricing of medicines : a taxonomy of approaches.PharmacoEconomics · 2013
    Article
13. Pharmacoeconomics.British journal of clinical pharmacology · 2012
    Article
14. Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.PharmacoEconomics · 2012
    Article
15. Defining rewardable innovation in drug therapy.Nature reviews. Drug discovery · 2012
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as